Michael Wang, M.D., Ph.D., Chief Strategy Officer, Author at NFCR

Michael Wang, M.D., Ph.D., Chief Strategy Officer

Catching Cancer Cells on Their Way to Spreading

NEW NFCR-Supported Technology is Ready for Clinical Use With a better understanding of the genetic changes in cancer cells, and a move effective way to capture them, oncologists and scientists can be alerted to drug resistance and metastasis —allowing them to more quickly select new drugs or better therapies for…...

Read more

3 Important Tips For Immuno-Oncology Drug Treatment

Immuno-oncology (IO) drugs have demonstrated unprecedented benefits in the treatment of several types of cancer. The overall survival time of cancer patients treated by IO drugs have been dramatically extended, and in some cases, even late stage fatal cancers are brought into remission by the IO-based immunotherapy. IO drugs work…...

Read more